Skip to main content
SpringerLink
Log in

Antibody-Mediated Rejection in Reconstructive Transplantation

  • Chapter
  • First Online:
The Science of Reconstructive Transplantation

Part of the book series: Stem Cell Biology and Regenerative Medicine ((STEMCELL))

Abstract

Antibody-mediated rejection (AMR) is an important cause of graft loss following transplantation of solid organs. Diagnosis of AMR of kidney, liver, and cardiac allografts is based on several criteria, including graft dysfunction, histological evidence of injury, complement deposition, and the presence of donor-specific antibodies. These four criteria are reviewed in this chapter, in addition to the treatment options for AMR. AMR is rarely described in reports of vascularized composite allografts. Nonetheless, its prevalence is expected to increase as the frequency of organ transplantation increases. Therefore, teams involved in vascularized composite allotransplantation should be aware of our current knowledge about AMR and how it should be treated.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J, Looney RJ. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 2003;48(2):455–9. doi:10.1002/art.10764.

    Article  CAS  PubMed  Google Scholar 

  2. Bayry J, Lacroix-Desmazes S, Carbonneil C, Misra N, Donkova V, Pashov A, Chevailler A, Mouthon L, Weill B, Bruneval P, Kazatchkine MD, Kaveri SV. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood. 2003;101(2):758–65. doi:10.1182/blood-2002–05-1447.

    Article  CAS  PubMed  Google Scholar 

  3. Becker YT, Becker BN, Pirsch JD, Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant: Off J Am Soc Transplant Am Soc Transplant Surg. 2004;4(6):996–1001. doi:10.1111/j.1600–6143.2004.00454.x.

    Article  CAS  Google Scholar 

  4. Berger S, Daha M. Complement in glomerular injury. Semin Immunopathol. 2007;9 (4):375–84. doi:10.1007/s00281-007-0090-3.

    Article  Google Scholar 

  5. Blume OR, Yost SE, Kaplan B. Antibody-mediated rejection: pathogenesis, prevention, treatment, and outcomes. J Transplant. 2012;2012:201754. doi:10.1155/2012/201754.

    PubMed Central  PubMed  Google Scholar 

  6. Böhmig G, Regele H. Diagnosis and treatment of antibody-mediated kidney allograft rejection. Transpl Int. 2003;16(11):773–87. doi:10.1007/s00147-003-0658-3.

    Article  PubMed  Google Scholar 

  7. Bohmig GA, Exner M, Habicht A, Schillinger M, Lang U, Kletzmayr J, Saemann MD, Horl WH, Watschinger B, Regele H. Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol. 2002;13(4):1091–99.

    CAS  PubMed  Google Scholar 

  8. Bonnefoy-Berard N, Revillard JP. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. J Heart Lung Transplant: Off Publ Int Soc Heart Transplant. 1996;15(5):435–42.

    CAS  Google Scholar 

  9. Bonnefoy-Berard N, Vincent C, Revillard JP. Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins. Transplantation. 1991;51(3):669–73.

    Article  CAS  PubMed  Google Scholar 

  10. Brooks P, Fuertes G, Murray RZ, Bose S, Knecht E, Rechsteiner MC, Hendil KB, Tanaka K, Dyson J, Rivett J. Subcellular localization of proteasomes and their regulatory complexes in mammalian cells. Biochem J. 2000;346(Pt 1):155–61.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Burns JM, Cornell LD, Perry DK, Pollinger HS, Gloor JM, Kremers WK, Gandhi MJ, Dean PG, Stegall MD. Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation. Am J Transplant. 2008;8(12):2684–94. doi:10.1111/j.1600-6143.2008.02441.x.

    Article  CAS  PubMed  Google Scholar 

  12. Calame KL. Plasma cells: finding new light at the end of B cell development. Nat Immunol. 2001;2(12):1103–8. doi:10.1038/ni1201-1103.

    Article  CAS  PubMed  Google Scholar 

  13. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99(3):754–8.

    Article  CAS  PubMed  Google Scholar 

  14. Cendales LC, Xu H, Bacher J, Eckhaus MA, Kleiner DE, Kirk AD. Composite tissue allotransplantation: development of a preclinical model in nonhuman primates. Transplantation. 2005;80(10):1447–54.

    Article  PubMed  Google Scholar 

  15. Cendales LC, Kanitakis J, Schneeberger S, Burns C, Ruiz P, Landin L, Remmelink M, Hewitt CW, Landgren T, Lyons B, Drachenberg CB, Solez K, Kirk AD, Kleiner DE, Racusen L. The Banff 2007 working classification of skin-containing composite tissue allograft pathology. Am J Transplant: Off J Am Soc Transplant Am Soc Transplant Surg. 2008;8(7):1396–400. doi:10.1111/j.1600–6143.2008.02243.x.

    Article  CAS  Google Scholar 

  16. Cerny T, Borisch B, Introna M, Johnson P, Rose AL. Mechanism of action of rituximab. Anti-Cancer Drugs. 2002;13(Suppl 2):S3–10.

    Article  CAS  PubMed  Google Scholar 

  17. Crespo M, Pascual M, Tolkoff-Rubin N, Mauiyyedi S, Collins AB, Fitzpatrick D, Farrell ML, Williams WW, Delmonico FL, Cosimi AB, Colvin RB, Saidman SL. Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics. Transplantation. 2001;71(5):652–8.

    Article  CAS  PubMed  Google Scholar 

  18. Cunningham-Rundles C, Zhou Z, Mankarious S, Courter S. Long-term use of IgA-depleted intravenous immunoglobulin in immunodeficient subjects with anti-IgA antibodies. J Clin Immunol. 1993;13 (4):272–8.

    Article  CAS  PubMed  Google Scholar 

  19. Chopek MW, Simmons RL, Platt JL. ABO-incompatible kidney transplantation: initial immunopathologic evaluation. Transplant Proc. 1987;19(6):4553–7.

    CAS  PubMed  Google Scholar 

  20. Dankof A, Schmeding M, Morawietz L, Günther R, Krukemeyer M, Rudolph B, Koch M, Krenn V, Neumann U. Portal capillary C4d deposits and increased infiltration by macrophages indicate humorally mediated mechanisms in acute cellular liver allograft rejection. Virchows Arch. 2005;447(1):87–93. doi:10.1007/s00428-005-1245-z.

    Article  PubMed  Google Scholar 

  21. Delves PJ, Martin SM, Burton DR, Roitt IM. Rott's Essential Immunology. 12th edn. Singapore: Blackwell Publishing Ltd.; 2011.

    Google Scholar 

  22. Demetris AJ, Minervini M, Nalesnik M, Ochoa E, Randhawa P, Sasatomi E, Wu T. Histopathology of liver transplantation. In: Ruiz P, editor. Transplantation pathology. New York: Cambridge University Press; 2009. pp. 111–84.

    Google Scholar 

  23. Feucht HE, Schneeberger H, Hillebrand G, Burkhardt K, Weiss M, Riethmuller G, Land W, Albert E. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int. 1993;43(6):1333–8.

    Article  CAS  PubMed  Google Scholar 

  24. Feucht HE, Lederer SR, Kluth B. Humoral alloreactivity in recipients of renal allografts as a risk factor for the development of delayed graft function. Transplantation. 1998;65(5):757–8.

    Article  CAS  PubMed  Google Scholar 

  25. Fidler ME, Gloor JM, Lager DJ, Larson TS, Griffin MD, Textor SC, Schwab TR, Prieto M, Nyberg SL, Ishitani MB, Grande JP, Kay PA, Stegall MD. Histologic findings of antibody-mediated rejection in ABO blood-group-incompatible living-donor kidney transplantation. Am J Transplant: Off J Am Soc Transplant Am Soc Transplant Surg. 2004;4(1):101–7.

    Article  Google Scholar 

  26. Fletcher J, Nankivell B, Alexander S. Chronic allograft nephropathy. Pediatr Nephrol. 2009;24(8):1465–71. doi:10.1007/s00467-008-0869-z.

    Article  PubMed Central  PubMed  Google Scholar 

  27. Gebel HM, Bray RA, Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk. Am J Transplant: Off J Am Soc Transplant Am Soc Transplant Surg. 2003;3(12):1488–500.

    Article  Google Scholar 

  28. Gelfand EW. Antibody-directed therapy: past, present, and future. J Allergy Clin Immunol. 2001;108(4 Suppl):S111–6.

    Article  CAS  PubMed  Google Scholar 

  29. Genberg H, Hansson A, Wernerson A, Wennberg L, Tyden G. Pharmacodynamics of rituximab in kidney transplantation. Transplantation. 2007;84(12 Suppl):S33–6. doi:10.1097/01.tp.0000296122.19026.0f.

    Article  CAS  PubMed  Google Scholar 

  30. Glotz D, Haymann JP, Sansonetti N, Francois A, Menoyo-Calonge V, Bariety J, Druet P. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg). A potential tool for transplantation of immunized patients. Transplantation. 1993;56(2):335–7.

    Article  CAS  PubMed  Google Scholar 

  31. Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, Diehl L, Lin WY, Hu Z, Lu Y, Chen Y, Wu Y, Meng YG, Gribling P, Lin Z, Nguyen K, Tran T, Zhang Y, Rosen H, Martin F, Chan AC. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol (Baltim, Md: 1950). 2005;174(2):817–26.

    Article  CAS  Google Scholar 

  32. Gonzalez-Stawinski GV, Yu PB, Love SD, Parker W, Davis RD Jr. Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab). Clin Immunol (Orlando, Fla). 2001;98(2):175–9. doi:10.1006/clim.2000.4980.

    Article  CAS  Google Scholar 

  33. Hautz T, Engelhardt TO, Weissenbacher A, Kumnig M, Zelger B, Rieger M, Rumpold G, Pierer G, Ninkovic M, Gabl M, Piza-Katzer H, Pratschke J, Margreiter R, Brandacher G, Schneeberger S. World experience after more than a decade of clinical hand transplantation: update on the Innsbruck program. Hand Clin. 2011;27(4):423–31.

    Article  PubMed  Google Scholar 

  34. Hautz T, Zelger B, Brandacher G, Mueller H, Grahammer J, Zelger B, Andrew Lee WP, Cavadas P, Margreiter R, Pratschke J, Schneeberger S. Histopathologic characterization of mild rejection (grade I) in skin biopsies of human hand allografts. Transpl Int. 2012;25(1):56–63. doi:10.1111/j.1432-2277.2011.01369.x.

    Article  PubMed  Google Scholar 

  35. Jackson G, Einsele H, Moreau P, Miguel JS. Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies. Cancer Treat Rev. 2005;31(8):591–602. doi:10.1016/j.ctrv.2005.10.001.

    Article  CAS  PubMed  Google Scholar 

  36. Jordan S, Cunningham-Rundles C, McEwan R. Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications. Am J Transplant: Off J Am Soc Transplant Am Soc Transplant Surg. 2003;3(6):653–64.

    Article  Google Scholar 

  37. Jordan SC, Vo AA, Peng A, Toyoda M, Tyan D. Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant: Off J Am Soc Transplant Am Soc Transplant Surg. 2006;6(3):459–66. doi:10.1111/j.1600–6143.2005.01214.x.

    Article  CAS  Google Scholar 

  38. Kanitakis J, McGregor B, Badet L, Petruzzo P, Morelon E, Devauchelle B, Dubernard JM. Absence of c4d deposition in human composite tissue (hands and face) allograft biopsies: an immunoperoxidase study. Transplantation. 2007;84(2):265–7. doi:10.1097/01.tp.0000266899.93315.52.

    Article  CAS  PubMed  Google Scholar 

  39. Kaufman CL, Ouseph R, Blair B, Kutz JE, Tsai TM, Scheker LR, Tien HY, Moreno R, Ozyurekoglu T, Banegas R, Murphy E, Burns CB, Zaring R, Cook DF, Marvin MR. Graft vasculopathy in clinical hand transplantation. Am J Transplant. 2012;12 (4):1004–16. doi:10.1111/j.1600–6143.2011.03915.x.

    Article  CAS  PubMed  Google Scholar 

  40. Kayler LK, Farber JL, Colombe B, LaCava D, Friedewald JJ, Ratner LE. Characterization of rejection episodes in patients following positive crossmatch and ABO-incompatible live donor renal transplantation. Transpl Int. 2006;19(2):128–39. doi:10.1111/j.1432–2277.2005.00249.x.

    Article  CAS  PubMed  Google Scholar 

  41. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001;345(10):747–55. doi:10.1056/NEJMra993360.

    Article  CAS  PubMed  Google Scholar 

  42. Lai CK, Yang H-M, Ra S, Fishbein MC. Pathology of cardiac transplantation. In: Ruiz P, editor. Transplantation pathology. New York: Cambridge University Press; 2009. pp. 185–216.

    Google Scholar 

  43. Landin L, Cavadas PC, Ibanez J, Roger I, Vera-Sempere F. CD3 + -mediated rejection and C4d deposition in two composite tissue (bilateral hand) allograft recipients after induction with alemtuzumab. Transplantation. 2009;87(5):776–81. doi:10.1097/TP.0b013e318198dbc7, 00007890-200903150-00024 [pii].

    Article  CAS  PubMed  Google Scholar 

  44. Lederer SR, Kluth-Pepper B, Schneeberger H, Albert E, Land W, Feucht HE. Impact of humoral alloreactivity early after transplantation on the long-term survival of renal allografts. Kidney Int. 2001;59(1):334–41. doi:10.1046/j.1523-1755.2001.00495.x.

    Article  CAS  PubMed  Google Scholar 

  45. Levine MH, Abt PL. Treatment options and strategies for antibody mediated rejection after renal transplantation. Semin Immunol. 2012;24(2):136–42. doi:10.1016/j.smim.2011.08.015.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  46. Locke JE, Magro CM, Singer AL, Segev DL, Haas M, Hillel AT, King KE, Kraus E, Lees LM, Melancon JK, Stewart ZA, Warren DS, Zachary AA, Montgomery RA. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant: Off J Am Soc Transplant Am Soc Transplant Surg. 2009;9(1):231–5. doi:10.1111/j.1600-6143.2008.02451.x.

    Article  CAS  Google Scholar 

  47. Lones MA, Czer LS, Trento A, Harasty D, Miller JM, Fishbein MC. Clinical-pathologic features of humoral rejection in cardiac allografts: a study in 81 consecutive patients. J Heart Lung Transplant: Off Int Soc Heart Transplant. 1995; 14(1 Pt 1):151–62.

    CAS  Google Scholar 

  48. Lucas JG, Co JP, Nwaogwugwu UT, Dosani I, Sureshkumar KK. Antibody-mediated rejection in kidney transplantation: an update. Expert Opin Pharmacother. 2011;12(4):579–92. doi:10.1517/14656566.2011.525219.

    Article  CAS  PubMed  Google Scholar 

  49. Lynch RJ, Platt JL. Accommodation in organ transplantation. Curr Opin Organ Transplant. 2008;13(2):165–70. doi:110.1097/MOT.1090b1013e3282f6391e.

    Article  PubMed Central  PubMed  Google Scholar 

  50. Mauiyyedi S, Crespo M, Collins AB, Schneeberger EE, Pascual MA, Saidman SL, Tolkoff-Rubin NE, Williams WW, Delmonico FL, Cosimi AB, Colvin RB. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol. 2002;13(3):779–87.

    PubMed  Google Scholar 

  51. Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M, Hahn S, Schreiber S, Wilhelm S, Herrmann M, Jack HM, Voll RE. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res. 2007;67(4):1783–92. doi:10.1158/0008-5472.can-06-2258.

    Article  CAS  PubMed  Google Scholar 

  52. Mohiuddin MM, Ogawa H, Yin D-P, Shen J, Galili U. Antibody-mediated accommodation of heart grafts expressing an incompatible carbohydrate antigen. Transplantation. 2003;75(3):258–62.

    Article  CAS  PubMed  Google Scholar 

  53. Montgomery RA, Zachary AA, Racusen LC, Leffell MS, King KE, Burdick J, Maley WR, Ratner LE. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation. 2000;70(6):887–95.

    Article  CAS  PubMed  Google Scholar 

  54. Nast CC, Cohen AH. Pathology of kidney transplantation. In: Danovitch GM, editor. Handbook of kidney transplantation. 2nd edn. Philadelphia: LWW; 2010. pp. 311–30.

    Google Scholar 

  55. Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K, Wiethe C, Winkler TH, Kalden JR, Manz RA, Voll RE. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med. 2008;14(7):748–55. doi:10.1038/nm1763.

    Article  CAS  PubMed  Google Scholar 

  56. Nickeleit V. The pathology of kidney transplantation. In: Ruiz P, editor. Transplantation pathology. New York: Cambridge University Press; 2009. pp. 45–110.

    Google Scholar 

  57. Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr., Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 2006;107(12):4907–16. doi:10.1182/blood-2005-08-3531.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  58. Okafor C, Ward DM, Mokrzycki MH, Weinstein R, Clark P, Balogun RA. Introduction and overview of therapeutic apheresis. J Apheresis. 2010;25(5):240–9. doi:10.1002/jca.20247.

    Article  Google Scholar 

  59. Park WD, Grande JP, Ninova D, Nath KA, Platt JL, Gloor JM, Stegall MD. Accommodation in ABO-incompatible kidney allografts, a novel mechanism of self-protection against antibody-mediated injury. Am J Transplant: Off J Am Soc Transplant Am Soc Transplant Surg. 2003;3(8):952–60.

    Article  CAS  Google Scholar 

  60. Pascual M, Saidman S, Tolkoff-Rubin N, Williams WW, Mauiyyedi S, Duan JM, Farrell ML, Colvin RB, Cosimi AB, Delmonico FL. Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation. 1998;66(11):1460–4.

    Article  CAS  PubMed  Google Scholar 

  61. Perry DK, Pollinger HS, Burns JM, Rea D, Ramos E, Platt JL, Gloor JM, Stegall MD. Two novel assays of alloantibody-secreting cells demonstrating resistance to desensitization with IVIG and rATG. Am J Transplant. 2008;8(1):133–43. doi:10.1111/j.1600-6143.2007.02039.x.

    Article  CAS  PubMed  Google Scholar 

  62. Petrossian GA, Nichols AB, Marboe CC, Sciacca R, Rose EA, Smith CR, Cannon PJ, Reemtsma K, Powers ER. Relation between survival and development of coronary artery disease and anti-HLA antibodies after cardiac transplantation. Circulation. 1989;80(5 Pt 2):III122–5.

    Google Scholar 

  63. Rault R, Piraino B, Johnston JR, Oral A. Pulmonary and renal toxicity of intravenous immunoglobulin. Clin Nephrol. 1991;36(2):83–6.

    CAS  PubMed  Google Scholar 

  64. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83(2):435–45.

    CAS  PubMed  Google Scholar 

  65. Rocha PN, Butterly DW, Greenberg A, Reddan DN, Tuttle-Newhall J, Collins BH, Kuo PC, Reinsmoen N, Fields T, Howell DN, Smith SR. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation. 2003;75(9):1490–5. doi:10.1097/01.tp.0000060252.57111.ac.

    Article  CAS  PubMed  Google Scholar 

  66. Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum. 2006;54(8):2377–86. doi:10.1002/art.22019.

    Article  CAS  PubMed  Google Scholar 

  67. Sapir T, Shoenfeld Y. Facing the enigma of immunomodulatory effects of intravenous immunoglobulin. Clin Rev Allergy Immunol. 2005;29(3):185–99. doi:10.1385/criai:29:3:185.

    Article  CAS  PubMed  Google Scholar 

  68. Sawada T, Fuchinoue S, Teraoka S. Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis. Transplantation. 2002;74(9):1207–10. doi:10.1097/01.tp.0000040990.15896.76.

    Article  CAS  PubMed  Google Scholar 

  69. Schneeberger S, Ninkovic M, Gabl M, Hussl H, Rieger M, Loescher W, Zelger B, Brandacher G, Bonatti H, Hautz T, Boesmueller C, Piza-Katzer H, Margreiter R. First forearm transplantation: outcome at 3 years. Am J Transplant. 2007;7(7):1753–62. doi:10.1111/j.1600–6143.2007.01837.x, AJT1837 [pii].

    Article  CAS  PubMed  Google Scholar 

  70. Schneeberger S, Gorantla VS, Brandacher G, Zeevi A, Demetris AJ, Lunz JG, Metes DM, Donnenberg AD, Shores JT, Dimartini AF, Kiss JE, Imbriglia JE, Azari K, Goitz RJ, Manders EK, Nguyen VT, Cooney DS, Wachtman GS, Keith JD, Fletcher DR, Macedo C, Planinsic R, Losee JE, Shapiro R, Starzl TE, Lee WPA. Upper-extremity transplantation using a cell-based protocol to minimize immunosuppression. Ann Surg. 2013;257(2):345–51. doi:310.1097/SLA.1090b1013e31826d31890bb.

    Article  PubMed Central  PubMed  Google Scholar 

  71. Schweitzer EJ, Wilson JS, Fernandez-Vina M, Fox M, Gutierrez M, Wiland A, Hunter J, Farney A, Philosophe B, Colonna J, Jarrell BE, Bartlett ST. A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplantation. 2000;70(10):1531–6.

    Article  CAS  PubMed  Google Scholar 

  72. Seemayer CA, Gaspert A, Nickeleit V, Mihatsch MJ. C4d staining of renal allograft biopsies: a comparative analysis of different staining techniques. Nephrol, Dial, Transplant: Off Publ Eur Dial Transplant Assoc—Eur Ren Assoc. 2007;22(2):568–76. doi:10.1093/ndt/gfl594.

    Article  Google Scholar 

  73. Semple JW, Kim M, Lazarus AH, Freedman J. Gamma-globulins prepared from sera of multiparous women bind anti-HLA antibodies and inhibit an established in vivo human alloimmune response. Blood. 2002;100(3):1055–9.

    Article  CAS  PubMed  Google Scholar 

  74. Shah A, Nadasdy T, Arend L, Brennan J, Leong N, Coppage M, Orloff M, Demme R, Zand MS. Treatment of C4d-positive acute humoral rejection with plasmapheresis and rabbit polyclonal antithymocyte globulin. Transplantation. 2004;77(9):1399–405.

    Article  CAS  PubMed  Google Scholar 

  75. Shapiro-Shelef M, Calame K. Plasma cell differentiation and multiple myeloma. Curr Opin Immunol. 2004;16(2):226–34. doi:10.1016/j.coi.2004.02.001.

    Article  CAS  PubMed  Google Scholar 

  76. Shapiro-Shelef M, Lin K-I, Savitsky D, Liao J, Calame K. Blimp-1 is required for maintenance of long-lived plasma cells in the bone marrow. J Exp Med. 2005;202(11):1471–6. doi:10.1084/jem.20051611.

    Google Scholar 

  77. Shepherd JC, Subramanian A, Montgomery RA, Samaniego MD, Gong G, Bergmann A, Blythe D, Dropulic L. West Nile virus encephalitis in a kidney transplant recipient. Am J Transplant: Off J Am Soc Transplant Am Soc Transplant Surg. 2004;4(5):830–3. doi:10.1111/j.1600–6143.2004.00410.x.

    Article  Google Scholar 

  78. Singh N, Pirsch J, Samaniego M. Antibody-mediated rejection: treatment alternatives and outcomes. Transplant Rev (Orlando, Fla). 2009;23(1):34–46. doi:10.1016/j.trre.2008.08.004.

    Article  Google Scholar 

  79. Stegall MD, Diwan T, Raghavaiah S, Cornell LD, Burns J, Dean PG, Cosio FG, Gandhi MJ, Kremers W, Gloor JM. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant: Off J Am Soc Transplant Am Soc Transplant Surg. 2011;11(11):2405–13. doi:10.1111/j.1600–6143.2011.03757.x.

    Article  CAS  Google Scholar 

  80. Takemoto SK, Zeevi A, Feng S, Colvin RB, Jordan S, Kobashigawa J, Kupiec-Weglinski J, Matas A, Montgomery RA, Nickerson P, Platt JL, Rabb H, Thistlethwaite R, Tyan D, Delmonico FL. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant. 2004;4(7):1033–41. doi:10.1111/j.1600–6143.2004.00500.x.

    Article  CAS  PubMed  Google Scholar 

  81. Tanemura M, Yin D, Chong AS, Galili U. Differential immune responses to α-gal epitopes on xenografts and allografts: implications for accommodation in xenotransplantation. J Clin Investig. 2000;105(3):301–10. doi:10.1172/jci7358.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  82. Tha-In T, Metselaar HJ, Tilanus HW, Boor PP, Mancham S, Kuipers EJ, de Man RA, Kwekkeboom J. Superior immunomodulatory effects of intravenous immunoglobulins on human T-cells and dendritic cells: comparison to calcineurin inhibitors. Transplantation. 2006;81(12):1725–34. doi:10.1097/01.tp.0000226073.20185.b1.

    Article  CAS  PubMed  Google Scholar 

  83. Tyan DB, Li VA, Czer L, Trento A, Jordan SC. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation. 1994;57(4):553–62.

    Article  CAS  PubMed  Google Scholar 

  84. Voso MT, Pantel G, Rutella S, Weis M, D’Alo F, Urbano R, Leone G, Haas R, Hohaus S. Rituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanisms. Haematologica. 2002;87(9):918–25.

    CAS  PubMed  Google Scholar 

  85. Wahrmann M, Exner M, Schillinger M, Haidbauer B, Regele H, Kormoczi GF, Horl WH, Bohmig GA. Pivotal role of complement-fixing HLA alloantibodies in presensitized kidney allograft recipients. Am J Transplant: Off J Am Soc Transplant Am Soc Transplant Surg. 2006;6 (5 Pt 1):1033–1041. doi:10.1111/j.1600–6143.2006.01285.x.

    Article  CAS  Google Scholar 

  86. Wang H, Arp J, Liu W, Faas SJ, Jiang J, Gies DR, Ramcharran S, Garcia B, Zhong R, Rother RP. Inhibition of terminal complement components in presensitized transplant recipients prevents antibody-mediated rejection leading to long-term graft survival and accommodation. J Immunol. 2007;179(7):4451–63.

    Article  CAS  PubMed  Google Scholar 

  87. Warren DS, Zachary AA, Sonnenday CJ, King KE, Cooper M, Ratner LE, Shirey RS, Haas M, Leffell MS, Montgomery RA. Successful renal transplantation across simultaneous ABO incompatible and positive crossmatch barriers. Am J Transplant: Off J Am Soc Transplant Am Soc Transplant Surg. 2004;4(4):561–8. doi:10.1111/j.1600–6143.2004.00364.x.

    Article  Google Scholar 

  88. Wassmuth R, Hauser IA, Schuler K, Erxleben H, Arnold ML, Koelman CA, Claas FH, Kalden JR. Differential inhibitory effects of intravenous immunoglobulin preparations on HLA-alloantibodies in vitro. Transplantation. 2001;71(10):1436–42.

    Article  CAS  PubMed  Google Scholar 

  89. Watanabe J, Scornik JC. IVIG and HLA antibodies. Evidence for inhibition of complement activation but not for anti-idiotypic activity. Am J Transplant: Off J Am Soc Transplant Am Soc Transplant Surg. 2005;5(11):2786–90. doi:10.1111/j.1600–6143.2005.01056.x.

    Article  CAS  Google Scholar 

  90. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol: Off J Am Soc Clin Oncol. 2003;21(21):3940–7. doi:10.1200/jco.2003.05.013.

    Article  CAS  Google Scholar 

  91. Wilkinson A, Kasiske BL. Long-term post-transplantration managment and complications. In: Danovitch GM. editor. Handbook of kidney transplantation. Philadelphia: Lippincott WIlliams & Wilkins; 2010. pp. 217–50.

    Google Scholar 

  92. Yang KS, Kenpe K, Yamaji K, Tsuda H, Hashimoto H. Plasma adsorption in critical care. Ther Apheresis: Off J Int Soc Apheresis Jpn Soc Apheresis. 2002;6(3):184–8.

    Article  Google Scholar 

  93. Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med. 1999;340(3):227–8. doi:10.1056/nejm199901213400311.

    Article  CAS  PubMed  Google Scholar 

  94. Zand MS, Vo T, Huggins J, Felgar R, Liesveld J, Pellegrin T, Bozorgzadeh A, Sanz I, Briggs BJ. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation. 2005;79(11):1507–15.

    Article  CAS  PubMed  Google Scholar 

  95. Zwirner J, Felber E, Herzog V, Riethmuller G, Feucht HE. Classical pathway of complement activation in normal and diseased human glomeruli. Kidney Int. 1989;36(6):1069–77.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Plastic and Reconstructive Surgery, La Paz University Hospital, Paseo de la Castellana, 261, 28046, Madrid, Spain

    Luis Landin MD, PhD, Pedro Bolado MD, PhD & Cesar Casado-Sanchez MD, PhD

Authors
  1. Luis Landin MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pedro Bolado MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cesar Casado-Sanchez MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luis Landin MD, PhD .

Editor information

Editors and Affiliations

  1. Plastic and Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

    Gerald Brandacher

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Landin, L., Bolado, P., Casado-Sanchez, C. (2015). Antibody-Mediated Rejection in Reconstructive Transplantation. In: Brandacher, G. (eds) The Science of Reconstructive Transplantation. Stem Cell Biology and Regenerative Medicine. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-2071-6_12

Download citation

Publish with us

Policies and ethics

Search

Navigation